WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in November:

Guggenheim Healthcare Innovation Conference (Boston)
Date: Wednesday, November 12, 2025
Time: 10:00am ET
Format: Fireside Chat
Webcast: Link

Jefferies Global Healthcare Conference (London)
Dates: November 17-20, 2025
Format: 1x1 Meetings

The live webcast of the fireside chat will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Investors interested in one-on-one meetings should contact their banking representatives.

About ProKidney Corp.

ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT^®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

ProKidney Contact
Ethan Holdaway
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Audra Friis 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact
Daniel Ferry
This email address is being protected from spambots. You need JavaScript enabled to view it.